Published 03-29-10
Submitted by CSL
CSL Limited (ASX:CSL), Australia's leading biopharmaceutical company, has released its first Corporate Responsibility Report, combining information about the Company's economic, social and environmental performance for 2009.
"CSL has experienced significant growth over the past 10 years, which has been underpinned by our commitment to conducting our business ethically and actively contributing to the well-being of our communities," said Dr. Brian McNamee, CEO and Managing Director of CSL Limited. "Our first Corporate Responsibility Report is an important demonstration of this ongoing commitment."
The report details CSL's approach to and performance in key areas of corporate responsibility. These include the Company's research into new medicines, its ongoing success in ensuring the safety and quality of its broad portfolio of therapies, providing a positive and healthy work environment for CSL employees, behaving responsibly in the global marketplace, and providing charitable support for communities in need around the world, while minimising the environmental impacts of its operations.
Highlights and statistics from some of these key areas include:
"As a global company, CSL recognises its role in responding to humanitarian emergencies around the world, from pandemics to earthquakes," said Dr. McNamee.
"Our support programs in developing countries help address pressing healthcare issues in our areas of expertise."
In 2009, CSL announced a US$3 million partnership with the World Federation of Hemophilia and pledged 3 million doses of pandemic H1N1 influenza vaccine to the World Health Organization. CSL also commissioned a study of antivenom access in Papua New Guinea and invested in new programs to help foster the next generation of medical researchers.
About CSL
The CSL Group has a combined heritage of outstanding contribution to medicine and human health with more than 90 years experience in the development and manufacture of vaccines and plasma protein biotherapies.
With major facilities in Australia, Germany, Switzerland and the US, CSL has more than 11,000 employees working in 27 countries.
For more information about CSL Limited and its 2009 Corporate Responsibility Report, visit www.csl.com.au.
CSL is a global specialty biopharmaceutical company that develops, manufactures and markets therapies to prevent and treat serious human disease. CSL employs over 11,000 people and operates in 27 countries. At CSL, Corporate Responsibility is about conducting our business ethically and contributing to the economic, social and environmental well-being of our communities.
More from CSL